Literature DB >> 19430903

The value of the serum neurofilament protein heavy chain as a biomarker for peri-operative brain injury after carotid endarterectomy.

Johann Sellner1, Axel Petzold, Suwad Sadikovic, Lorena Esposito, Martin S Weber, Peter Heider, Hans-Henning Eckstein, Bernhard Hemmer, Holger Poppert.   

Abstract

This prospective study examined the value of serum neurofilament protein levels for detecting peri-operative brain damage following carotid endarterectomy. An ELISA was used for quantification of neurofilament protein heavy chain (NfH(SMI35)) levels from patients undergoing endarterectomy for symptomatic (n = 17) and asymptomatic high-grade internal carotid artery stenosis (n = 30). All patients underwent diffusion-weighted brain imaging before and after the procedure. NfH(SMI35) levels were significantly higher in patients with a symptomatic carotid artery stenosis (0.131 ng/ml) if compared to asymptomatic patients (0.055 ng/ml, P = 0.01). However, serum NfH(SMI35) levels were not related to signs of brain ischemia on routine brain imaging techniques. Our pilot data suggests that raised NfH(SMI35) serum levels in patients with symptomatic carotid artery disease may be a sensitive biomarker for diffuse ischemic damage to the CNS. We conclude that NfH(SMI35) failed to qualify as a biomarker for peri-operative brain injury in CEA and factors that may have compromised the validation of this biomarker are discussed and need to be taken into account for the design of further studies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19430903     DOI: 10.1007/s11064-009-9976-x

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  22 in total

1.  A specific ELISA for measuring neurofilament heavy chain phosphoforms.

Authors:  A Petzold; G Keir; A J E Green; G Giovannoni; E J Thompson
Journal:  J Immunol Methods       Date:  2003-07       Impact factor: 2.303

Review 2.  Carotid endarterectomy--an evidence-based review: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

Authors:  S Chaturvedi; A Bruno; T Feasby; R Holloway; O Benavente; S N Cohen; R Cote; D Hess; J Saver; J D Spence; B Stern; J Wilterdink
Journal:  Neurology       Date:  2005-09-27       Impact factor: 9.910

3.  Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST)

Authors: 
Journal:  Lancet       Date:  1998-05-09       Impact factor: 79.321

4.  Postoperative cortical neural loss associated with cerebral hyperperfusion and cognitive impairment after carotid endarterectomy: 123I-iomazenil SPECT study.

Authors:  Kohei Chida; Kuniaki Ogasawara; Yasunori Suga; Hideo Saito; Masakazu Kobayashi; Kenji Yoshida; Yasunari Otawara; Akira Ogawa
Journal:  Stroke       Date:  2008-12-12       Impact factor: 7.914

Review 5.  Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century.

Authors:  Valery L Feigin; Carlene M M Lawes; Derrick A Bennett; Craig S Anderson
Journal:  Lancet Neurol       Date:  2003-01       Impact factor: 44.182

6.  Glial and axonal body fluid biomarkers are related to infarct volume, severity, and outcome.

Authors:  Axel Petzold; Patrik Michel; Michael Stock; Myriam Schluep
Journal:  J Stroke Cerebrovasc Dis       Date:  2008 Jul-Aug       Impact factor: 2.136

7.  Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomised controlled trial.

Authors:  A Halliday; A Mansfield; J Marro; C Peto; R Peto; J Potter; D Thomas
Journal:  Lancet       Date:  2004-05-08       Impact factor: 79.321

8.  Quantification of neurodegeneration by measurement of brain-specific proteins.

Authors:  A Petzold; D Baker; G Pryce; G Keir; E J Thompson; G Giovannoni
Journal:  J Neuroimmunol       Date:  2003-05       Impact factor: 3.478

9.  Phosphorylated neurofilament heavy chain is a marker of neurodegeneration in Leber hereditary optic neuropathy (LHON).

Authors:  John Guy; Gerry Shaw; Fred N Ross-Cisneros; Peter Quiros; Solange R Salomao; Adriana Berezovsky; Valerio Carelli; William J Feuer; Alfredo A Sadun
Journal:  Mol Vis       Date:  2008-12-22       Impact factor: 2.367

10.  Phosphorylation and compactness of neurofilaments in multiple sclerosis: indicators of axonal pathology.

Authors:  Axel Petzold; Djordje Gveric; Mike Groves; Klaus Schmierer; Donna Grant; Miles Chapman; Geoffrey Keir; Louise Cuzner; Edward J Thompson
Journal:  Exp Neurol       Date:  2008-06-20       Impact factor: 5.330

View more
  5 in total

1.  Hyperacute detection of neurofilament heavy chain in serum following stroke: a transient sign.

Authors:  Johann Sellner; Amit Patel; Pooja Dassan; Martin M Brown; Axel Petzold
Journal:  Neurochem Res       Date:  2011-07-27       Impact factor: 3.996

2.  Serial soluble neurofilament heavy chain in plasma as a marker of brain injury after cardiac arrest.

Authors:  Malin Rundgren; Hans Friberg; Tobias Cronberg; Bertil Romner; Axel Petzold
Journal:  Crit Care       Date:  2012-12-12       Impact factor: 9.097

3.  The diagnostic and prognostic value of neurofilament heavy chain levels in immune-mediated optic neuropathies.

Authors:  Axel Petzold; Gordon T Plant
Journal:  Mult Scler Int       Date:  2012-12-17

4.  Serum Phosphorylated Neurofilament-Heavy Chain, a Potential Biomarker, is Associated With Peripheral Neuropathy in Patients With Type 2 Diabetes.

Authors:  Xiaona Qiao; Shuo Zhang; Weiwei Zhao; Hongying Ye; Yehong Yang; Zhaoyun Zhang; Qing Miao; Renming Hu; Yiming Li; Bin Lu
Journal:  Medicine (Baltimore)       Date:  2015-11       Impact factor: 1.889

5.  Risk Factors for Delayed Neurocognitive Recovery According to Brain Biomarkers and Cerebral Blood Flow Velocity.

Authors:  Rasa Bukauskienė; Edmundas Širvinskas; Tadas Lenkutis; Rimantas Benetis; Rasa Steponavičiūtė
Journal:  Medicina (Kaunas)       Date:  2020-06-11       Impact factor: 2.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.